Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Camurus ABCAMRF +9.38%85 Cash-to-Debt is 37.53 as of Jun. 2026, which is 15% above its 10-year median of 32.66. GuruFocus rates CAMRF with a GF Score™ of 85/100 and a GF Value™ of $75.11 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,399 Biotechnology companies, Camurus AB ranks better than 69.12% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Camurus AB's cash to debt ratio for the quarter that ended in Jun. 2026 was 37.53.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Camurus ABcould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Camurus AB's Cash-to-Debt or its related term are showing as below:
CAMRF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 7.34 Med: 32.66 Max: No Debt
Current: 37.53
During the past 13 years, Camurus AB's highest Cash to Debt Ratio was No Debt. The lowest was 7.34. And the median was 32.66.
CAMRF's Cash-to-Debt is ranked better than 69.12% of 1399
companies
in the Biotechnology industry
Industry Median: 6.49
vs CAMRF: 37.53
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Camurus AB Cash-to-Debt Related Terms
Camurus AB Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Camurus AB's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
CAMRF vs VRTX, REGN, RVMD: Cash-to-Debt Comparison
For the Biotechnology subindustry, Camurus AB's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camurus AB Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camurus AB's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Camurus AB's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Camurus AB (CAMRF) has a Cash-to-Debt of 37.53 as of Jun. 2026. This is 15% above median its historical median of 32.66. Over the past decade, Camurus AB's Cash-to-Debt has ranged from 7.34 to 10,000.00. According to the industry distribution chart, Camurus AB ranks #432 out of 1399 companies in the Biotechnology industry, placing it in the top 30.9%.
Is Camurus AB's Cash-to-Debt too high?
Camurus AB's current Cash-to-Debt of 37.53 is 15% above median its 10-year median of 32.66. Over the past 10 years, this metric has ranged from a low of 7.34 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.49. Camurus AB's value of 37.53 is 478.3% above this industry median. Based on the distribution chart, Camurus AB ranks #432 out of 1399 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Camurus AB has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #432 out of 1399 companies for Cash-to-Debt. This puts Camurus AB in the upper half of its industry. The industry median Cash-to-Debt is 6.49. Camurus AB's value of 37.53 is 478.3% above this benchmark. Historically, Camurus AB's own Cash-to-Debt has ranged from 7.34 to 10,000.00 over the past decade. While the company's 10-year median is 32.66 vs. the industry median of 6.49, Camurus AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.49, based on 1,399 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Camurus AB's current Cash-to-Debt of 37.53 is 478.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Camurus AB's current Cash-to-Debt is 37.53, which is 15% above median its own 10-year median of 32.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Modestly Undervalued. The stock's GF Value™ is $75.11, compared to a current price of $64.00 — trading 14.8% below its estimated fair value. The current Cash-to-Debt is 37.53, which is 15% above median its 10-year median of 32.66 and 478.3% above the Biotechnology industry median of 6.49. Camurus AB's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Camurus AB (CAMRF), the current Cash-to-Debt is 37.53 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (CAMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of $64.00 is trading 14.8% below its estimated GF Value™ of $75.11.
GuruFocus considers Camurus AB to be Modestly Undervalued.
Key valuation signals for CAMRF:
Cash-to-Debt: 37.53 (15% above median its 10-year median of 32.66)
GF Value™: $75.11 vs. price of $64.00 (14.8% below fair value)
Industry Position: 478.3% above the Biotechnology median (#432 of 1399)
No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
85GF Score
Get the complete analysis for CAMRF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMRF has been successfully added to your 
